Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs)

Cardiovascular Toxicology

Volumn 12, Issue 2, 2012, Pages 123-134

  Liu, Yongmin ^a   Nguyen, Phuonggiang ^a   Baris, Tara Z ^a   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Electron microscopy; Extracellular acidification rate; H9c2; HL 1; Mitochondrial biogenesis; Mitochondrial protein expression; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitors; Oxygen consumption rate

Indexed keywords

DIDANOSINE PLUS ZIDOVUDINE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSCRIPTION FACTOR NRF1; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; BIOGENESIS; CELL DAMAGE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ELECTRON MICROSCOPY; GLYCOLYSIS; HEART MUSCLE CELL; MITOCHONDRIAL RESPIRATION; MORPHOLOGY; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; CELL LINE; CELL LINE, TRANSFORMED; CELL PROLIFERATION; MICE; MITOCHONDRIA; MYOCYTES, CARDIAC; RATS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS; RODENTIA; VASCONCELLEA CANDICANS;

EID: 84864662572     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9148-5     Document Type: Article

References (40)

1. HIV/AIDS Statistics and Surveillance, CDC. Available from: http://www.cdc.gov/hiv/topics/surveillance/basic.htm. Accessed July 1, 2011.
2. Condra, J. H., Miller, M. D., Hazuda, D. J., & Emini, E. A. (2002). Potential new therapies for the treatment of HIV-1 infection. Annual Review of Medicine, 53, 541-555.
3. Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine, 331, 1173-1180.
4. Mofenson, L. M. (2004). Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 Serosurvey of childbearing women. Archives of Pediatrics and Adolescent Medicine, 158, 422-425.
5. Watts, D. H. (2006). Treating HIV during pregnancy: An update on safety issues. Drug Safety, 29, 467-490.
6. Lewis, W., Day, B. J., & Copeland, W. C. (2003). Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nature Reviews Drug Discovery, 2, 812-822.
7. Moyle, G. (2000). Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clinical Therapeutics, 22, 911-936.
8. Nolan, D., & Mallal, S. (2004). Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antiviral Therapy, 9, 849-863.
9. Poirier, M. C., Olivero, O. A., Walker, D. M., & Walker, V. E. (2004). Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicology and Applied Pharmacology, 199, 151-161.
10. Carter, M. M., Torres, S. M., Cook, D. L., Jr., McCash, C. L., Yu, M., Walker, V. E., et al. (2007). Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environmental and Molecular Mutagenesis, 48, 239-247.
11. Escobar, P. A., Olivero, O. A., Wade, N. A., Abrams, E. J., Nesel, C. J., Ness, R. B., et al. (2007). Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environmental and Molecular Mutagenesis, 48, 330-343.
12. Meng, Q., Olivero, O. A., Fasco, M. J., Bellisario, R., Kaminsky, L., Pass, K. A., et al. (2007). Plasma and cellular markers of 3'-azido-3'- dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environmental and Molecular Mutagenesis, 48, 307-321.
13. Walker, D. M., Kajon, A. E., Torres, S. M., Carter, M. M., McCash, C. L., Swenberg, J. A., et al. (2009). WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication. Environmental and Molecular Mutagenesis, 50, 460-472.
14. Borojerdi, J. P., Ming, J., Cooch, C., Ward, Y., Semino-Mora, C., Yu, M., et al. (2009). Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells. Mutation Research, 665, 67-74.
15. Olivero, O. A., Anderson, L. M., Diwan, B. A., Haines, D. C., Harbaugh, S. W., Moskal, T. J., et al. (1997). Transplacental effects of 3'-azido-2', 3'-dideoxythymidine (AZT): Tumorige-nicity in mice and genotoxicity in mice and monkeys. Journal of the National Cancer Institute, 89, 1602-1608.
16. Diwan, B. A., Riggs, C. W., Logsdon, D., Haines, D. C., Olivero, O. A., Rice, J. M., et al. (1999). Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. Toxicology and Applied Pharmacology, 161, 82-99.
17. Koczor, C. A., & Lewis, W. (2010). Nucleoside reverse trans-criptase inhibitor toxicity and mitochondrial DNA. Expert Opinion on Drug Metabolism & Toxicology, 6, 1493-1504.
18. Lugassy, D. M., Farmer, B. M., & Nelson, L. S. (2010). Metabolic and hepatobiliary side effects of antiretroviral therapy (ART). Emergency Medicine Clinics of North America, 28, 409-419.
19. Benhammou, V., Tardieu, M., Warszawski, J., Rustin, P., & Blanche, S. (2007). Clinical mitochondrial dysfunction in unin-fected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environmental and Molecular Mutagenesis, 48, 173-178.
20. Blanche, S., Tardieu, M., Benhammou, V., Warszawski, J., & Rustin, P. (2006). Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS, 20, 1685-1690.
21. Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Fir-tion, G., et al. (1999). Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet, 354, 1084-1089.
22. Meng, Q., Grosovsky, A. J., Shi, X., & Walker, V. E. (2000). Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymi-dine. Mutagenesis, 15, 405-410.
23. Barret, B., Tardieu, M., Rustin, P., Lacroix, C., Chabrol, B., Desguerre, I., et al. (2003). Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS, 17, 1769-1785.
24. Lipshultz, S. E., Shearer, W. T., Thompson, B., Rich, K. C., Cheng, I., Orav, E. J., et al. (2010). Cardiac effects of antiretro-viral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIVExposed Infants and Children cohort study). Journal of the American College of Cardiology, 57, 76-85.
25. Liu, Y., Borchert, G. L., Surazynski, A., & Phang, J. M. (2008). Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene, 27, 6729-6737.
26. Divi, R. L., Leonard, S. L., Kuo, M. M., Walker, B. L., Orozco, C. C., St Claire, M. C., et al. (2005). Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardio vascular Toxicology, 5, 333-346.
27. Claycomb, W. C., Lanson, N. A., Jr., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., et al. (1998). HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proceedings of the National Academy Science USA, 95, 2979-2984.
28. Kimes, B. W., & Brandt, B. L. (1976). Properties of a clonal muscle cell line from rat heart. Experimental Cell Research, 98, 367-381.
29. Rasbach, K. A., & Schnellmann, R. G. (2007). Signaling of mitochondrial biogenesis following oxidant injury. Journal of Biological Chemistry, 282, 2355-2362.
30. Liner, K. J., 2nd, Ro, M. J., & Robertson, K. R. (2010). HIV, antiretroviral therapies, and the brain. Current HIV/AIDS Reports, 7, 85-91.
31. Schouten, J., Cinque, P., Gisslen, M., Reiss, P., & Portegies, P. (2010). HIV-1 infection and cognitive impairment in the cART era: A review. AIDS, 25, 561-575.
32. Kohler, J. J., & Lewis, W. (2007). A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environmental and Molecular Mutagenesis, 48, 166-172.
33. Beeson, C. C., Beeson, G. C., & Schnellmann, R. G. (2010). A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Analytical Biochemistry, 404, 75-81.
34. Arnaudo, E., Dalakas, M., Shanske, S., Moraes, C. T., DiMauro, S., & Schon, E. A. (1991). Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet, 337, 508-510.
35. Scarpulla, R. C. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological Reviews, 88, 611-638.
36. Rowe, G. C., Jiang, A., & Arany, Z. (2010). PGC-1 coactivators in cardiac development and disease. Circulation Research, 107, 825-838.
37. Schon, E. A., DiMauro, S., Hirano, M., & Gilkerson, R. W. (2010). Therapeutic prospects for mitochondrial disease. Trends in Molecular Medicine, 16, 268-276.
38. Lee, H. C., & Wei, Y. H. (2005). Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. International Journal of Biochemistry and Cell Biology, 37, 822-834.
39. Olivero, O. A., Fernandez, J. J., Antiochos, B. B., Wagner, J. L., St Claire, M. E., & Poirier, M. C. (2002). Transplacental geno-toxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. Journal of Acquired Immune Deficiency Syndromes, 29, 323-329.
40. Torres, S. M., Walker, D. M., Carter, M. M., Cook, D. L., McCash, C. L., Cordova, E. M., et al. (2007). Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environmental and Molecular Mutagenesis, 48(3-4), 224-238.